Surgical staging of low-risk Stage IA endometrioid endometrial cancers

Purpose: Surgical staging in early endometrial cancer is not universally done and lymphadenectomy in early-stage disease is controversial. Aim of the present study was to evaluate surgical staging in patients with endometrioid histology, FIGO Stage IA endometrial cancer. Materials and Methods: Eighty-seven patients with FIGO Stage IA, low-risk patients were included in the study. Staging surgery group included patients who had comprehensive surgical staging (hysterectomy, oophorectomy, and pelvic lymph node dissection with or without para-aortic lymph node dissection). Non-staging surgery group included patients who had hysterectomy, and bilateral oophorectomy with or without lymph node sampling. Two groups were compared for lymph node status, occult cervical involvement, other prognostic factors, and outcome were analyzed. Results: In total 17.2% of patients were upstaged in final pathological examination; 12.9% in non-staging surgery group and 24.2% in staging surgery group. Upstaging was due to lymph node involvement (6%), cervical stromal invasion (13.7%), and myometrial invasion greater than 50% (1.1%). Median pelvic lymph node number was 23 and pelvic lymph node metastases was found in 3% of the patients. Median para-aortic lymph node number was 11.5 and there was one isolated para-aortic lymph node metastases (5.8%). Conclusion: Of the patients, 17.2% had stage migration. Until the issue is solved by future studies, surgical staging might be considered standard surgery for endometrial cancer.

Endometrial cancer; Staging; Lymph node dissection; Upstaging.

[1] Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al.: “GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11”. Lyon, France: International Agency for Research on Cancer; 2014. Available at: http://globocan.iarc.fr

[2] SEER Stat Fact Sheets: “Endometrial cancer”. Available at: http://seer.cancer.gov/statfacts/html/corp.html

[3] Höckel M., Dornhöfer N.: “Treatment of early endometrialcarcinoma: is less more?”. Lancet. 2009,10,97.

[4] Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B.: “Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study”. Cancer, 1987, 60, 2035.

[5] Mutch D.G.: “The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas”. Gynecol. Oncol. 2009, 115, 325.

[6] Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al.: “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrialadenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744.

[7] Kost E.R., Hall K.L., Hines J.F., Farley J.H., Nycum L.R., Rose G.S., et al.: “Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer”. Gynecol. Oncol., 2003, 89, 218.

[8] Todo Y., Kato H., Kaneuchi M., Watari H., Takeda M., Sakuragi N.: “Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis”. Lancet, 2010, 375, 1165.

[9] Mohan D.S., Samuels M.A., Selim M.A., Shalodi A.D., Ellis R.J., Samuels J.R., Yun H.J.: “Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma”. Gynecol. Oncol.,1998, 70, 165.

[10] Cragun J.M., Havrilesky L.J., Calingaert B., Synan I., Secord A.A., Soper J.T., et al.: “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer”. J. Clin. Oncol., 2005, 23, 3668.

[11] Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Noojin F. 3rd., Conner W.: “Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling”. Gynecol. Oncol., 1995, 56, 29.

[12] Abu-Rustum N.R., Iasonos A., Zhou Q., Oke E., Soslow R.A., Alektiar K.M., et al.: “Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?”. Am. J. Obstet. Gynecol., 2008, 198, 457e1.

[13] ASTEC study group, Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K.: “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study”. Lancet, 2009, 10, 125.

[14] Benedetti Panici P., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G., et al.: “Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial”. J. Natl. Cancer. Inst., 2008, 3, 1707.

[15] Mariani A., Dowdy S.C., Cliby W.A., Gostout B.S., Jones M.B., Wilson T.O., Podratz K.C.: “Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging”. Gynecol. Oncol., 2008, 109, 11.

[16] Amant F., Neven P., Vergote I.: “Lymphadenectomy in endometrial cancer”. Lancet, 2009, 4, 1169.

[17] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., Podratz K.C.: “Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?”. Am. J. Obstet. Gynecol., 2000, 182, 1506.

[18] Rungruang B., Olawaiye A.B.: “Comprehensive Surgical Staging for Endometrial Cancer”. Rev. Obstet. Gynecol., 2012, 5, 28.

[19] Chi D.S., Barakat R.R., Palayekar M.J., Levine D.A., Sonoda Y., Alektiar K., et al.: “The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology”. Int. J. Gynecol. Cancer, 2008, 18, 269.

[20] Orr J., Holimon J., Orr P.: “Stage I corpus cancer: Is teletherapy necessary?”. Am. J. Obstet. Gynecol., 1997, 1176, 777.

[21] Sigurdson E.R.: “Lymph node dissection: is it diagnostic or therapeutic?”. J. Clin. Oncol., 2003, 15, 965.

[22] Barnes M.N., Kilgore L.C.: “Complete surgical staging of early endometrial adenocarcinoma: optimizing patient outcomes”. Semin. Radiat. Oncol., 2000, 10, 3.

[23] Moore D.H., Fowler W.C. Jr., Walton L.A., Droegemueller W.: “Morbidity of lymph node sampling in cancers of the uterine corpus and cervix”. Obstet. Gynecol., 1989, 174, 180.

[24] Akin O., Mironov S., Pandit-Taskar N., Hann L.E.: “Imaging of uterine cancer”. Radiol. Clin. North Am., 2007, 45, 167.

[25] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E.: “Relationship between surgical– pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1991, 40, 55.

[26] Fadare O., Desrosiers L., Xiao Z.F., Wang S.A.: “How often does cervical involvement upstage patients with non-myoinvasive (otherwise stage 1A) endometrioid adenocarcinoma of the endometrium?”. Virchows. Arch., 2007, 450, 601.

[27] Takano M., Ochi H., Takei Y., Miyamoto M., Hasumi Y., Kaneta Y., et al.. “Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?”. Br. J. Cancer, 2013, 1, 1760.

[28] Elshaikh M.A., Al-Wahab Z., Mahdi H., Albuquerque K., Mahan M., Kehoe S.M., et al.: “Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study”. Gynecol. Oncol., 2015, 136, 235.

[29] Kwon J.S., Francis J.A., Qiu F., Weir M.M., Ettler H.C.: “When is a pathology review indicated in endometrial cancer?”. Obstet. Gynecol., 2007, 110, 1224.

[30] Benedet J.L., Hacker N.F., Ngan H.Y.S.: “Staging classifications and clinical practice guidelines of gynaecologic cancers”. Int. J. Gynecol. Obstet., 2000, 70, 207.